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Abstract
Background: Targeted delivery of nerve growth factor (NGF) has emerged as a potential therapy for Alzheimer’s
disease (AD) due to its regenerative effects on basal forebrain cholinergic neurons. This hypothesis has been tested in
patients with AD using encapsulated cell biodelivery of NGF (NGF-ECB) in a first-in-human study. We report our results
from a third-dose cohort of patients receiving second-generation NGF-ECB implants with improved NGF secretion.
Methods: Four patients with mild to moderate AD were recruited to participate in an open-label, phase Ib dose
escalation study with a 6-month duration. Each patient underwent stereotactic implant surgery with four NGF-ECB
implants targeted at the cholinergic basal forebrain. The NGF secretion of the second-generation implants was
improved by using the Sleeping Beauty transposon gene expression technology and an improved three-dimensional
internal scaffolding, resulting in production of about 10 ng NGF/device/day.
Results: All patients underwent successful implant procedures without complications, and all patients completed the
study, including implant removal after 6 months. Upon removal, 13 of 16 implants released NGF, 8 implants released
NGF at the same rate or higher than before the implant procedure, and 3 implants failed to release detectable
amounts of NGF. Of 16 adverse events, none was NGF-, or implant-related. Changes from baseline values of cholinergic
markers in cerebrospinal fluid (CSF) correlated with cortical nicotinic receptor expression and Mini Mental State
Examination score. Levels of neurofilament light chain (NFL) protein increased in CSF after NGF-ECB implant, while glial
fibrillary acidic protein (GFAP) remained stable.
Conclusions: The data derived from this patient cohort demonstrate the safety and tolerability of sustained NGF
release by a second-generation NGF-ECB implant to the basal forebrain, with uneventful surgical implant and removal
of NGF-ECB implants in a new dosing cohort of four patients with AD.
Trial registration: ClinicalTrials.gov identifier: NCT01163825. Registered on 14 Jul 2010.
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Background
An estimated 44 million individuals worldwide have de-
mentia, the majority of whom have Alzheimer’s disease
(AD) [1]. Common to patients with AD is an early loss
of basal forebrain cholinergic neurons, resulting in de-
generation of cortical and hippocampal projections [2].
Pre-clinical and clinical observations indicate a strong
association between cholinergic dysfunction and cogni-
tive impairment in patients with AD [3, 4] that lead to
the development of cholinesterase inhibitors (ChEIs).
Cholinergic degeneration is, in part, the result of im-
paired nerve growth factor (NGF) signalling and trans-
port to the basal forebrain cholinergic neurons [5]. NGF
is neuroprotective for basal forebrain cholinergic neu-
rons and reduces cognitive deficits in animal models of
AD [6, 7]. However, NGF does not cross the blood-brain
barrier, owing to its chemical properties, and requires
targeted delivery to the brain to have a biological effect.
A constraint has been the difficulty in identifying a mode
of administration that selectively provides long-term de-
livery of NGF in sufficient quantities to target areas of
the brain to achieve clinical efficacy. Several strategies of
direct delivery have been investigated, including direct
central nervous system (CNS) infusion [8], intra-nasal
administration [9], gene therapy approaches [10] and
cell-based delivery using stem cells [11]. Each approach
has advantages as well as practical and technical restric-
tions limiting further development. Intra-ventricular in-
fusion of NGF in three patients with AD resulted in
positive effects on nicotinic binding and cerebral blood
[12]. However, the patients developed significant side ef-
fects, such as back pain and weight loss, making this
route of NGF administration unsuitable [8]. Animal
studies later indicated that these adverse events were
caused by NGF binding to dorsal root ganglion neurons
and the hypothalamus, eliciting a pain response and
weight loss [13]. None of these adverse effects was seen
following intra-parenchymal NGF administration in ro-
dents [14]. The safety of intra-parenchymal NGF deliv-
ery was further substantiated by the fact that no pain
was experienced by patients with Parkinson’s disease
who were receiving NGF infusion directly into the stri-
atum [15] or by cognitively impaired primates following
transplant of NGF-secreting fibroblasts to the basal fore-
brain [16].
This latter approach was tested in a clinical trial of ex
vivo gene delivery of NGF to the basal forebrain in pa-
tients with AD, and the treatment was well-tolerated,
without any adverse effects being attributed to NGF
[10]. NGF delivery via CERE-110, an adeno-associated
virus-based gene delivery vector encoding for human
NGF, showed sustained NGF expression in rodents for
12 months [17], and it was found to be safe and well-
tolerated in patients with AD in a 2-year pilot study [18].
However, with this in vivo gene therapy approach, there
are certain limitations and safety concerns, including per-
manent genetic modification of brain cells and the inability
to control or stop release of bioactive substance.
To circumvent these limitations, we applied an encap-
sulated cell technology (encapsulated cell biodelivery
[ECB]) [19] developed by NsGene A/S, Ballerup,
Denmark. The implant is a catheter-like device contain-
ing a genetically engineered, NGF-secreting, human cell
line housed behind a semi-permeable, hollow fibre
membrane at its tip. This encapsulation is immunoisola-
tory and protects the transplanted allogeneic cell line
from host immune system rejection while nutrients, oxy-
gen and the NGF produced can diffuse freely across the
wall of the capsule. An advantage of the ECB technology
over traditional ex vivo or in vivo gene therapy ap-
proaches is that the NGF delivery can be stopped by re-
moving the device that contains the genetically modified
NGF-producing cells from the brain.
We explored ECB of NGF (NGF-ECB) in six patients
with AD in a phase Ib study in three dose cohorts,
and results from the third cohort are reported here.
Results from earlier dose cohorts were previously re-
ported [20, 21], and they demonstrated safety and
feasibility, lower rates of brain atrophy, stable cogni-
tive function, and improvement in cerebrospinal fluid
(CSF) cholinergic markers in a subset of patients [22, 23].
NGF release upon explant was low, albeit detectable, and
viable cells were observed. We developed a second-
generation NGF-ECB implant to achieve increased sus-
tained release of NGF that was validated in pre-clinical
animal studies [24]. The primary objective of the present
study was to assess the safety and tolerability of device
and cell-line combination for a second-generation NGF-




We report the results of an open-label dose escalation
phase Ib study of targeted delivery of NGF to the cholin-
ergic basal forebrain in four patients with mild to mod-
erate AD for a 6-month duration. The first two dosing
cohorts of three patients each received implants of a
first-generation NGF-ECB device (NsG0202) (Fig. 1)
[20]. The present dose cohort consisted of four patients
who received implants of a second-generation NGF-ECB
device left in place for 6 months. The aims of the study
were to assess safety and tolerability, device perform-
ance, clinical efficacy and AD biomarkers.
Participants
Patients were recruited and enrolled into the study from
the Memory Clinic, Karolinska University Hospital,
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Huddinge, Sweden. The primary inclusion criteria were
(1) a probable diagnosis of mild to moderate AD accord-
ing to the National Institute of Neurological and Commu-
nicative Disorders and Stroke-Alzheimer’s Disease and
Related Disorders Association criteria [25], (2) aged 50–80
years, (3) Mini Mental State Examination (MMSE) [26]
score of 15–24, (4) living at home with a caregiver and (5)
stable treatment with ChEIs for at least 3 months before
enrolment as well as during the study. Exclusion criteria
included (1) ongoing medical and/or psychiatric condi-
tions, (2) antipsychotic drug treatment and (3) smoking
(so as not to interfere with nicotinic binding on positron
emission tomography [PET]; see paragraph Positron Emis-
sion Tomography). To exclude significant neurological
conditions contraindicating surgery, we performed brain
magnetic resonance imaging (MRI) for all patients. A clin-
ician (HE) established the diagnosis of probable AD based
on the above-described criteria, which was reviewed by
the principal investigator (ME). Patients and caregivers
gave us written informed consent prior to enrolment. The
Swedish Medical Products Agency and the Regional Hu-
man Ethics Committee of Stockholm approved the study.
NGF-ECB implant
The NsG0202.1 implant is a gene therapy medicinal
product consisting of NGC-0211 cells expressing human
NGF, and it is encapsulated in a pre-assembled device.
The cells are derived from the ARPE-19 human retinal
pigment epithelial (RPE) cell line (American Type
Culture Collection, Manassas, VA, USA), transfected,
and modified with the human NGF gene as described
previously [24]. Briefly, ARPE-19 cells were co-transfected
with separate plasmids coding for human NGF and a
Sleeping Beauty (SB) transposase [27]. The NGF plasmid
contains the neomycin antibiotic resistance gene, and sev-
eral stable clones were selected and tested in vitro and in
vivo. The NGC-0211 cell line showed stable long-term
performance in experimental devices tested in animal
models and was selected as the clinical cell line. The cell
line was tested for safety according to regulatory guide-
lines, and it was characterized with respect to secreted
NGF bioactivity, processing and amino acid sequence be-
fore clinical application.
The NsG0202.1 implant was produced under Good
Manufacturing Practice (GMP), as previously described
for NsG0202 [21]. Briefly, a 150-mm-long, 1-mm-
wide, hollow, barium-impregnated polyurethane tether
(Carbothane; Lubrizol Corp., Wickliffe, OH, USA) was
attached to an 11-mm-long, polyethersulphone, hol-
low fibre membrane (AkzoNobel/Membrana/3 M,
Wuppertal, Germany) via a titanium linker (Heraeus
Materials, S.A., Yverdon-les-Bains, Switzerland). The
semi-permeable hollow fibre membrane has an outer
diameter of 0.72 mm and a mean molecular weight
cut-off of 280 kDa. The pre-assembled and gamma-
sterilized device was in turn filled with GMP banked
NGC-0211 cells a few weeks before implant. A shelf-
life of 4.5 weeks after product release was validated
to allow ample time for the implant procedure. The poly-
vinyl alcohol sponge matrix used in the first-generation
NsG0202 device was replaced with a polyester terephthal-
ate yarn matrix as an internal cell-supportive scaffold
(Fig. 2). This matrix allowed for improved cell adherence,
cell survival, and manufacturability. NsG0202.1 implants
were tested for safety and toxicology in pre-clinical animal
studies [24]. They were kept in sealed, sterile containers
filled with human endothelial serum-free medium (Life
Technologies, Carlsbad, CA, USA) at 37 °C for up to
4.5 weeks and tested for sterility, mycoplasma, cell
leakage and NGF production. On the basis of in vitro
analysis, implants releasing NGF within a range of
7.4–10.8 ng NGF/device/24 h were selected for implant.
Fig. 1 Schematic representation of the dose escalation regimen of the study
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Surgical procedures
The details of the surgical procedure and the description
of the technical platform with the first-generation NGF-
ECB device were reported in 2012 [21]. Briefly, patients
underwent MRI-guided stereotactic implant procedures
with two NsG0202.1 implants in each hemisphere while
under general anaesthesia. The anatomical targets were
the centre of the nucleus basalis of Meynert (Ch4) and
the vertical limb of the diagonal band of Broca (Ch2) in
the basal forebrain. Definition of the anatomical targets
was performed using brain atlas coordinates [28] and
modified according to each patient’s brain anatomy. The
patients underwent cranial computed tomography (CT)
immediately after the surgical procedure for safety as-
sessment and documentation of implant positions by
using an image fusion technique (Elekta AB, Stockholm,
Sweden). At the end of the study, all four patients
underwent surgical removal of the implants under gen-
eral anaesthesia according to the protocol described pre-
viously [20].
Implant function
During the explant procedure, the tethers of retrieved
implants were cut and the cell-containing capsules
were placed in 1 ml of human endothelial serum-free
medium (Life Technologies) and analysed for NGF as
previously described [21]. Results were expressed in
nanograms NGF per 24 h after extrapolation for incu-
bation time. For evaluation of cell survival and
morphology, cell capsules were fixed in a 4 % forma-
lin solution, dehydrated in a graded ethanol series,
and embedded in historesin (Leica Microsystems,
Wetzlar, Germany). Sections (5 μm) were mounted on
slides coated with poly-L-lysine and stained with
hematoxylin and eosin (VWR Bie & Berntsen A/S,
Søborg, Denmark).
Histopathology
A cortical brain biopsy was performed at the entry
point of one of four implants (at a cortical gyrus of
the frontal lobe, 20 mm anterior to the coronary su-
ture and 30–50 mm lateral to midline) in each pa-
tient. Tissue was immediately fixed in 4 %
paraformaldehyde solution, and 5-μm-thick paraffin
sections were cut and stained with antibodies against
hyperphosphorylated tau (clone AT-8, 1:500 dilution;
Fujirebio Europe, Zwijnaarde, Belgium) and β-amyloid
(clone 6F/3D, 1:400 dilution; DakoCytomation, Glostrup,
Denmark). The product was visualized using the Zymed
Lab-SA detection system (Life Technologies).
Clinical assessments
The primary outcome measures were safety and toler-
ability of NsG0202.1 as assessed by reports of adverse
events (AEs), vital signs, concomitant medications, pain
(assessed with a visual analogue scale), body mass index
and laboratory tests. Physical and neurological examina-
tions and cranial MRI were performed at baseline and at
3 and 6 months to verify implant positions and to screen
for signs of haemorrhage, infarction, infection, oedema
or necrosis. Secondary outcome measures included cog-
nition (assessed with MMSE and Alzheimer’s Disease
Assessment Scale-Cognitive subscale [ADAS-Cog] [29]),
CSF biomarkers, brain atrophy seen on MRI scans, and
biomarkers of cholinergic function (nicotinic receptor
binding on PET and CSF cholinergic biomarkers) at
baseline and at 3 and 6 months.
Magnetic resonance imaging
All patients were scanned on a 1.5-T Magnetom Avanto
MRI scanner (Siemens, Erlangen, Germany) as previ-
ously described [22]. Full brain and skull coverage was
obtained, and quality control was carried out on all
Fig. 2 Schematic representation of the NsG0202.1 device
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images according to previously published criteria [30].
Data processing was performed with FreeSurfer 5.1.0
software (http://surfer.nmr.mgh.harvard.edu/) as detailed
elsewhere [22]. Visual quality control was performed,
and an index of global brain atrophy was calculated as
follows: brain volume (BV)/CSF index = (total grey
matter volume + total white matter volume)/total CSF
volume. Lower values of the BV/CSF index represent
greater brain atrophy.
Positron emission tomography
Measurements of regional cerebral blood flow and cere-
bral nicotinic receptor binding were performed using a
dual-tracer protocol including 15O-water and (S)-N-
[11C-methyl]nicotine [31]. A flow-compensated param-
eter, K*2, was calculated from the rate constant K2 for
nicotine divided by cerebral blood flow [32]. A low K*2
value indicates high 11C-nicotinic binding. 11C-nicotinic
binding was expressed as a percentage increase from
baseline value, calculated by using the following formula:
100 −% K*2 = 100 − (K2(f )*/K2(b)*100), where f and b in-
dicate the time of observation (3 and 6 months) and
baseline, respectively. No baseline data were present for
patient 1, owing to technical difficulties with the PET
nicotine tracer. For the purpose of calculating change
from baseline for this patient, the mean value for base-
line 11C-nicotinic binding for the other three patients
was calculated and extrapolated as the baseline value for
patient 1.
Laboratory tests
Routine blood (serum) and CSF samples were collected
at baseline and at 3 and 6 months. Serum and CSF
samples were aliquoted into polypropylene tubes and
stored at −80 °C until analysis. Analyses of CSF amyloid-
beta peptide 1–42 (Aβ1–42, Aβ), total tau (t-tau) and
phosphorylated tau 181 (p-tau) were performed with
xMAP technology using the INNO-BIA AlzBio3 kit
(Fujirebio Europe) as previously described [33]. CSF
levels of neurofilament light chain protein (NFL) and
glial fibrillary acidic protein (GFAP) were analysed using
previously described enzyme-linked immunosorbent
assay (ELISA) methods [34, 35]. CSF activity of acetyl-
cholinesterase (AChE) was assessed by using the modi-
fied Ellman’s colorimetric assay, and protein levels of
AChE were assessed by employing a functional ELISA as
described previously [36]. Activity and protein levels in
CSF of choline acetyltransferase (ChAT) were measured
by using a recently developed colorimetric assay [37].
All NGF-ECB implants were analysed for NGF release
and cell viability by ELISA and histology. An assay for
NGF (ELISA kit, minimal detection level 31 pg/ml; R&D
Systems, Minneapolis, MN, USA) and ELISA for detec-
tion of anti-NGF antibodies in serum and CSF were
validated by Vecura AB, Stockholm, Sweden, according
to Good Laboratory Practice.
Statistical analyses
Statistical analyses were performed at an individual level
using each patient’s own baseline value as a control. The
Wilcoxon signed-rank test was used to compare baseline
data with 3- and 6-month post-operative time points.
Spearman’s rank correlations were used to investigate
relationships between variables. A p value <0.05 was
deemed significant in all statistical tests. The IBM SPSS
22.0 (IBM, Armonk, NY, USA) and Statistica 7.0 (StatSoft,




The study population included four patients (three men
and one woman). The median age of the group was
64 years (range 57–68), and the median MMSE and
ADAS-Cog scores at screening were 21 points (range
16–23) and 29 points (range 23–35), respectively. All pa-
tients were treated with ChEI as concomitant medica-
tions with a median duration of 17 months (range 5–60)
before inclusion, and they remained on ChEI treatment
throughout the study. All patients were treated for
hypertension and were normotensive at the time of
inclusion. Three patients had a medical history of de-
pression, and one patient was taking levothyroxine for
a hypothyroid condition but was euthyroid at inclu-
sion. Brain glucose metabolism, assessed with PET
imaging at baseline, was consistent with an AD diag-
nosis in all four patients. The AD diagnosis was con-
firmed histologically on Aβ- and tau-positive cortical
biopsies from the implant site in all four patients
(data not shown).
Safety and tolerability
A total of 16 AEs were reported during the study. The
most common AEs were mild post-operative headache
and transient post-operative delirium (Table 1). No ser-
ious AE was reported, but one AE was of medical im-
portance: a left sub-acute subdural haematoma (SDH)
discovered incidentally by MRI at the 3-month follow-
up. The haematoma was in a parieto-occipital location
with local mass effect but no midline shift. The haema-
toma did not extend frontally to the two implants on the
left side and did not displace the implants from their tar-
geted positions in the basal forebrain. The patient devel-
oped slight fatigue, but no focal neurological signs were
found. The haematoma was managed conservatively and
resolved within 3 months. There was no indication of
weight loss or back pain in any of the patients. No sign
of blood-brain barrier dysfunction was found, based on
Eyjolfsdottir et al. Alzheimer's Research & Therapy  (2016) 8:30 Page 5 of 11
CSF/albumin ratio assessment. All AEs were resolved by
the end of the trial period at 6 months.
Surgical procedures
All study participants underwent surgery according to
the study protocol without complications. Post-operative
cranial CT scans confirmed that NGF-ECB implants
were positioned in the intended anatomical targets with-
out adverse radiographic findings. Overall, the post-
operative course was uneventful, and the surgical scalp
incisions healed well in all patients. The implants
remained in position during the study period and were
easily removed by the end of the study without any com-
plications or safety concerns. Implants were sent for
NGF analyses and histology, and patients were dis-
charged two days after surgery.
Cognition and magnetic resonance imaging
Cognition was assessed on the basis of performance on
clinical rating scales. At baseline, the median MMSE
score was 21 (range 16–23), and the median ADAS-Cog
score was 29 (range 23–35). All patients showed declines
of 2–3 points on the MMSE (median 19, range 14–21)
and increased by 3–6 points on the ADAS-Cog (median
33, range 26–41) during the study. Cognitive decline
was paralleled by a decrease in mean BV/CSF index
value [38] at 6 months (16.2 ± 0.7) compared with base-
line (18.7 ± 1.6), without reaching statistical significance
(Z = −1.826, p = 0.068). The patients were followed clin-
ically for an additional 20 months after implant removal.
Three patients continued to follow the same rate of
decline in MMSE score after implant removal, while one
patient showed a steeper rate of cognitive decline (data
not shown).
Cerebrospinal fluid analyses
No anti-NGF antibodies were detected in CSF at 3 or
6 months for any of the four patients, and NGF levels in
CSF were below the detection limit of the assay (ELISA)
at baseline and at 3 and 6 months. Compared with base-
line, levels of Aβ, t-tau and p-tau did not change signifi-
cantly at 3- or 6-month follow-up (Table 2). Levels of
CSF NFL were increased in all patients at 3 months but
had decreased at the 6-month time point, although not
to baseline levels. This change in NFL levels was not
paralleled by an increase in CSF GFAP (Table 2). CSF
ChAT and AChE activities were increased in two of the
four patients at 6 months compared with baseline. These
increased activities coincided with a lesser decline in
MMSE compared with the other two patients, and we
found a significant positive correlation between change
in MMSE score and change in ChAT or AChE activity
from baseline to 6 months, respectively (Fig. 3a, b).
In vivo 11C-nicotinic binding by positron emission
tomography
We found no increase in regional 11C-nicotinic binding
across individual patients. However, changes from base-
line in 11C-nicotinic binding in whole brain correlated
positively with changes in CSF ChAT and AChE activ-
ities (Fig. 3d, e). Furthermore, change from baseline in
11C-nicotinic binding in whole brain correlated signifi-
cantly with change in MMSE score (Fig. 3c).
Implant performance
Sixteen NsG0202.1 implants were selected for
implanting. The selected implants released a mean ± SD
of 8.6 ± 2.2 ng NGF/24 h pre-operatively, five times higher
than the first-generation NsG0202 implant used for the
first two dose cohorts [21]. All implants were retrieved at
6 months and proved to be intact with no adherence of in-
flammatory cells or connective tissue. Figure 4 shows the
histology of implants number 4 (patient 1) and number 23
(patient 4) after explant. Viable cells can be seen in clus-
ters between cell-supportive scaffolds inside the hollow
membrane capsule. The majority of capsules were identi-
fied with continued secretion of NGF. All but 3 implants
released NGF, and 9 of 16 devices released more NGF at
the end of the study than at baseline. Following a peak
value at day 1 following retrieval, the rate of NGF release
stabilized at 24–48 h. On the basis of measures of sus-
tained release in vitro at day 2, the values of total NGF re-
leased per patient per 24 h were 24.4 ng, 23.4 ng, 27.3 ng
and 148.8 ng (Fig. 5).
Discussion
We report on a dose escalation step of an ongoing phase
I study of ECB-NGF to the cholinergic basal forebrain in
patients with mild to moderate AD. The safety and toler-
ability of a second-generation NGF-ECB implant was ex-
plored in four patients for 6 months, and thereafter the
implants were explanted. We demonstrate that







Nasopharyngitis (common cold) 1
Abnormal clinical chemistry findingsa 1
Nausea/vomiting 1
Herpes simplex blister 1
Total number 16
aHypokalaemia
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stereotactic deep brain implant of NGF-ECB is feasible
and safe and that sustained release of NGF to the target
areas is well-tolerated. Implants demonstrated robust
cell survival correlating with NGF release. Furthermore,
we found a significant correlation between cognition and
cholinergic markers in CSF and in brain, for change
from baseline compared with the end of the study.
Due to suboptimal gene expression and limited cell
survival in the first-generation implant at explant, we de-
veloped a second-generation NGF-ECB implant with
several modifications for a dose escalation step. First, we
replaced the polyvinyl alcohol scaffolding with a polyes-
ter terephthalate yarn that provided better support for
the cells and improved cell survival (not shown) and
manufacturability. To produce greater NGF secretion, we
generated regulation-compliant, clonal, NGF-secreting
ARPE-19 cell lines using an SB transposon expression sys-
tem [39]. This technology uses a transposase that mediates
genomic integration of multiple copies of the transgene
inserted between two transposon terminal inverted
Table 2 Cerebrospinal fluid biomarkers at baseline and at 3 and 6 months
BL, median (range) 3 months, median (range) p Value vs. BL 6 months, median (range) p Value vs. BL
Aβ1–42, ng/L 188 (134–208) 202 (113–207) 1.0 183 (123–206) 0.27
t-tau, ng/L 128 (70–235) 120 (64–256) 1.0 113 (76–187) 0.46
p-tau, ng/L 36 (18–76) 42 (35–48) 1.0 46 (33–55) 0.72
NFL, ng/L 301 (57–557) 1959 (846–2632) 0.07 718 (236–758) 0.07
GFAP, ng/L 586 (395–891) 612 (387–943) 0.72 589 (353–833) 1.0
ChAT activity, nmol/ml/minute 373 (317–447) 367 (279–414) 0.14 358 (337–410) 0.47
AChE activity, nmol/ml/minute 12 (9–22) 10 (9–21) 0.07 10 (9–23) 0.27
Abbreviations: BL baseline, Aβ1–42 amyloid-β peptide 1–42, t-tau total tau, p-tau phosphorylated tau, NFL neurofilament light chain protein, GFAP glial fibrillary
acidic protein, ChAT choline acetyltransferase, AChE acetylcholine esterase
Fig. 3 Percentage change from baseline in cerebrospinal fluid (CSF) activities of choline acetyltransferase (ChAT) and acetylcholinesterase (AChE)
correlated positively with change from baseline in Mini Mental State Examination (MMSE) score (a and b) and nicotinic binding in whole brain
(d and e), respectively. The baseline value for nicotinic binding for patient 1 was extrapolated from an average of baseline values from patients
2–4 and is indicated by a circle. Change from baseline in nicotinic binding correlated positively with change from baseline in MMSE score (c).
Change from baseline in AChE activity correlated positively with change from baseline in ChAT activity (f)
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repeats [27]. SB transposon-mediated gene delivery has
been explored in several animal models of genetic disor-
ders, as well as in a first-in-human application in oncology
[40].
To our knowledge, our present study is the first re-
ported clinical application of ex vivo SB transposon-
mediated gene delivery to the CNS. The vector system is
capable of stable gene transfer with long-term expres-
sion at an efficacy comparable with that of viral systems
[41]. The NGC-0211 cell line showed at least a ten-fold
higher NGF expression than the previously used cell
line, NGC-0295, and secreted correctly processed bio-
active NGF without any significant amount of pro-NGF.
Together, these revisions yielded improved cell viability
with a five-fold increase in NGF release compared with
the first-generation implant. Following explant of
implants at 6 months, the in vitro NGF analyses con-
firmed that all four patients had been administered NGF
during the entire study, with three of the patients receiv-
ing similar doses, while three of four implants retrieved
from one patient released higher NGF levels at explant
than at implant, albeit without any adverse clinical
findings.
Targeted delivery of NGF to the cholinergic basal fore-
brain was suggested as a potential disease-modifying
treatment in 1990 [16], and the first clinical pilot study
employed an ex vivo technique using NGF-secreting fi-
broblasts stereotactically implanted in the basal fore-
brain [10]. In one deceased study subject, histology of
the basal forebrain confirmed trophic effects of NGF
mirrored by sprouting of cholinergic neurons. A similar
observation was made in a subsequent phase I study
Fig. 4 Histology from two nerve-growth-factor- encapsulated cell biodelivery implants taken from (a) patient 1 (implant number 4) and (b)
patient 4 (implant number 23) after explant. Original magnifications × 10, ×40 and × 100, as indicated
Fig. 5 Mean release of nerve growth factor from nerve-growth-factor-encapsulated cell biodelivery implants represented in nanograms per
patient per 24 h, before implant (pre-implant) and at day 2 after explant (post-explant day 2) in the four patients
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using the adeno-associated CERE-110 delivery vector,
with post mortem pathology showing cholinergic hyper-
trophy 4 years after gene delivery [18]. In contrast to
vector-based NGF gene delivery, the ECB technology
has several advantages from a patient safety perspective.
First, the grafted cells are encapsulated and isolated from
the host cells, making it possible to remove the cells in
case of complications and reducing the risk of graft-
versus-host rejection. In addition, the implant can be re-
placed with a new or modified cell capsule as part of
dose escalation or dose de-escalation using an indwelling
catheter without stereotactic surgery [42]. Second, there
is no genetic manipulation of host cells, minimizing the
risk of mutations and carcinogenesis. Third, the risk of
down-regulation of transgene expression is reduced be-
cause there is no physical contact between the host and
encapsulated cells. Fourth, the secretion of NGF occurs
along the entire length of the semi-permeable mem-
brane, allowing for a controlled and potentially greater
distribution of NGF to the basal forebrain than possible
with viral vector gene delivery [43]. Cell encapsulation
technology has advanced to become a viable therapeutic
option for chronic disorders of the CNS [19].
Previous studies of NGF delivery to patients with AD
have demonstrated improved cognition [10], cerebral
glucose metabolism, nicotinic binding and electro-
encephalogram pattern [8, 12] in a subset of patients. In
our present study, none of the patients showed im-
proved cognition during the 6-month study period,
which was expected, considering the short duration of
the trial. However, there was no evidence of cognitive
decline greater than expected for a 6-month period, also
consistent with previous reports [44]. Levels of CSF AD
biomarkers Aββ and tau proteins did not change signifi-
cantly during the study period. Levels of CSF NFL, a
marker of acute tissue damage [45], were increased in all
patients at 3 months but had decreased at the 6-month
time point, although not to baseline levels. This
phenomenon was also observed in previous dose cohorts
of this study [20]. In all cohorts in this study, a small
cortical biopsy was taken for the purpose of diagnosis
prior to implanting of the ECB device and would have
contributed to the increase in CSF NFL levels. In a study
of deep brain stimulation electrode implant in patients
with Parkinson’s disease, researchers have also reported
an associated increase in CSF NFL levels, a sign of lim-
ited acute brain tissue damage, immediately following
electrode implant and then a decline over several
months [46].
CSF levels of ChAT and AChE were similar to those
detected in patients in previous dose cohorts of this
study [23]. Consistent with our previous findings, we
found a positive correlation between changes in MMSE
during the study and changes from baseline in the three
in vivo markers of cholinergic activity: (1) the acetylcho-
line synthesizer (ChAT), (2) degrading enzyme (AChE)
activities and (3) nicotinic receptors. We found no sig-
nificant positive effect on BV by MRI, while results de-
rived from previous dose cohorts showed a slower rate
of brain atrophy by MRI in a subset of patients during
NGF administration [22]. However, a 6-month study
period is probably too short to capture structural brain
changes in patients with AD.
An SDH was the only clinically significant AE in this
dose cohort and the second one reported in this study.
Similarly to the previous SDH, it was diagnosed inciden-
tally on the basis of the 3-month MRI and was managed
conservatively. In both patients, the haematomas were
localized away from the site of implant and did not dis-
locate the implants. Both patients continued to partici-
pate in the study and did not develop any sequelae
related to the SDH.
Conclusions
Safety and tolerability was demonstrated for the NGF-
ECB technology with a second-generation device capable
of sustained release of NGF in the majority of 16 implants
at 6 months (3 implants did not release measurable
amounts of NGF at explant). No AEs were deemed to be
related to NGF or the device. These data support further
development of ECB technology for treatment of AD and
other neurodegenerative disorders. The design of implants
is under further refinement to obtain a more predictable
and stable long-term targeted NGF delivery to the brain in
patients with AD. Future studies in AD need to be carried
out for at least 18 months to better capture positive effects
on the cholinergic system and associated cognitive im-
provement in randomised controlled trials.
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